Literature DB >> 22318154

Discovery of potential diagnostic and vaccine antigens in herpes simplex virus 1 and 2 by proteome-wide antibody profiling.

Mina Kalantari-Dehaghi1, Sookhee Chun, Aziz Alami Chentoufi, Jozelyn Pablo, Li Liang, Gargi Dasgupta, Douglas M Molina, Algis Jasinskas, Rie Nakajima-Sasaki, Jiin Felgner, Gary Hermanson, Lbachir BenMohamed, Philip L Felgner, D Huw Davies.   

Abstract

Routine serodiagnosis of herpes simplex virus (HSV) infections is currently performed using recombinant glycoprotein G (gG) antigens from herpes simplex virus 1 (HSV-1) and HSV-2. This is a single-antigen test and has only one diagnostic application. Relatively little is known about HSV antigenicity at the proteome-wide level, and the full potential of mining the antibody repertoire to identify antigens with other useful diagnostic properties and candidate vaccine antigens is yet to be realized. To this end we produced HSV-1 and -2 proteome microarrays in Escherichia coli and probed them against a panel of sera from patients serotyped using commercial gG-1 and gG-2 (gGs for HSV-1 and -2, respectively) enzyme-linked immunosorbent assays. We identified many reactive antigens in both HSV-1 and -2, some of which were type specific (i.e., recognized by HSV-1- or HSV-2-positive donors only) and others of which were nonspecific or cross-reactive (i.e., recognized by both HSV-1- and HSV-2-positive donors). Both membrane and nonmembrane virion proteins were antigenic, although type-specific antigens were enriched for membrane proteins, despite being expressed in E. coli.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22318154      PMCID: PMC3318641          DOI: 10.1128/JVI.05194-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  82 in total

Review 1.  Sorting out the new HSV type specific antibody tests.

Authors:  R L Ashley
Journal:  Sex Transm Infect       Date:  2001-08       Impact factor: 3.519

2.  Immunodominance among herpes simplex virus-specific CD8 T cells expressing a tissue-specific homing receptor.

Authors:  David M Koelle; Zhi Liu; Christopher L McClurkan; Randal C Cevallos; Jeffrey Vieira; Nancy A Hosken; Clement A Meseda; Devon C Snow; Anna Wald; Lawrence Corey
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-17       Impact factor: 11.205

3.  Variance stabilization applied to microarray data calibration and to the quantification of differential expression.

Authors:  Wolfgang Huber; Anja von Heydebreck; Holger Sültmann; Annemarie Poustka; Martin Vingron
Journal:  Bioinformatics       Date:  2002       Impact factor: 6.937

4.  A variance-stabilizing transformation for gene-expression microarray data.

Authors:  B P Durbin; J S Hardin; D M Hawkins; D M Rocke
Journal:  Bioinformatics       Date:  2002       Impact factor: 6.937

5.  T cell immunity to herpes simplex viruses in seronegative subjects: silent infection or acquired immunity?

Authors:  Christine M Posavad; Anna Wald; Nancy Hosken; Meei Li Huang; David M Koelle; Rhoda L Ashley; Lawrence Corey
Journal:  J Immunol       Date:  2003-04-15       Impact factor: 5.422

6.  Time course of seroconversion by HerpeSelect ELISA after acquisition of genital herpes simplex virus type 1 (HSV-1) or HSV-2.

Authors:  Rhoda Ashley-Morrow; Elizabeth Krantz; Anna Wald
Journal:  Sex Transm Dis       Date:  2003-04       Impact factor: 2.830

7.  Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity.

Authors:  Lbachir BenMohamed; Georges Bertrand; Cory D McNamara; Helene Gras-Masse; Juergen Hammer; Steven L Wechsler; Anthony B Nesburn
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

8.  Glycoprotein-D-adjuvant vaccine to prevent genital herpes.

Authors:  Lawrence R Stanberry; Spotswood L Spruance; Anthony L Cunningham; David I Bernstein; Adrian Mindel; Stephen Sacks; Stephen Tyring; Fred Y Aoki; Moncef Slaoui; Martine Denis; Pierre Vandepapeliere; Gary Dubin
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

9.  Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant.

Authors:  Zane A Brown; Anna Wald; R Ashley Morrow; Stacy Selke; Judith Zeh; Lawrence Corey
Journal:  JAMA       Date:  2003-01-08       Impact factor: 56.272

Review 10.  Recent progress in herpes simplex virus immunobiology and vaccine research.

Authors:  David M Koelle; Lawrence Corey
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

View more
  26 in total

1.  Immunodominant "asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals.

Authors:  Gargi Dasgupta; Aziz A Chentoufi; Mina Kalantari; Payam Falatoonzadeh; Sookhee Chun; Chang Hyun Lim; Philip L Felgner; D Huw Davies; Lbachir BenMohamed
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

2.  Rapid immunodiagnostics of multiple viral infections in an acoustic microstreaming device with serum and saliva samples.

Authors:  Neha Garg; Dylan Boyle; Arlo Randall; Andy Teng; Jozelyn Pablo; Xiaowu Liang; David Camerini; Abraham P Lee
Journal:  Lab Chip       Date:  2019-04-23       Impact factor: 6.799

3.  Current status and prospects for development of an HSV vaccine.

Authors:  Christine Johnston; David M Koelle; Anna Wald
Journal:  Vaccine       Date:  2013-09-06       Impact factor: 3.641

Review 4.  Asymptomatic memory CD8+ T cells: from development and regulation to consideration for human vaccines and immunotherapeutics.

Authors:  Arif Azam Khan; Ruchi Srivastava; Patricia Prado Lopes; Christine Wang; Thanh T Pham; Justin Cochrane; Nhi Thi Uyen Thai; Lucas Gutierrez; Lbachir Benmohamed
Journal:  Hum Vaccin Immunother       Date:  2014-02-05       Impact factor: 3.452

5.  Laser Adjuvant-Assisted Peptide Vaccine Promotes Skin Mobilization of Dendritic Cells and Enhances Protective CD8+ TEM and TRM Cell Responses against Herpesvirus Infection and Disease.

Authors:  Patricia P Lopes; George Todorov; Thanh T Pham; Anthony B Nesburn; Elmostafa Bahraoui; Lbachir BenMohamed
Journal:  J Virol       Date:  2018-03-28       Impact factor: 5.103

Review 6.  Developments and Applications of Functional Protein Microarrays.

Authors:  Guan-Da Syu; Jessica Dunn; Heng Zhu
Journal:  Mol Cell Proteomics       Date:  2020-04-17       Impact factor: 5.911

7.  Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine.

Authors:  Xavier Dervillez; Chetan Gottimukkala; Khaled W Kabbara; Chelsea Nguyen; Tina Badakhshan; Sarah M Kim; Anthony B Nesburn; Steven L Wechsler; Lbachir Benmohamed
Journal:  Future Virol       Date:  2012-04-01       Impact factor: 1.831

8.  Human Asymptomatic Epitopes Identified from the Herpes Simplex Virus Tegument Protein VP13/14 (UL47) Preferentially Recall Polyfunctional Effector Memory CD44high CD62Llow CD8+ TEM Cells and Protect Humanized HLA-A*02:01 Transgenic Mice against Ocular Herpesvirus Infection.

Authors:  Ruchi Srivastava; Arif A Khan; Sumit Garg; Sabrina A Syed; Julie N Furness; Hawa Vahed; Tiffany Pham; Howard T Yu; Anthony B Nesburn; Lbachir BenMohamed
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

Review 9.  The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine.

Authors:  Tiffany Kuo; Christine Wang; Tina Badakhshan; Sravya Chilukuri; Lbachir BenMohamed
Journal:  Vaccine       Date:  2014-10-16       Impact factor: 3.641

10.  CXCL17 Chemokine-Dependent Mobilization of CXCR8+CD8+ Effector Memory and Tissue-Resident Memory T Cells in the Vaginal Mucosa Is Associated with Protection against Genital Herpes.

Authors:  Ruchi Srivastava; Marcela Hernández-Ruiz; Arif A Khan; Mona A Fouladi; Grace J Kim; Vincent T Ly; Taikun Yamada; Cynthia Lam; Sheilouise A B Sarain; Undariya Boldbaatar; Albert Zlotnik; Elmostafa Bahraoui; Lbachir BenMohamed
Journal:  J Immunol       Date:  2018-03-16       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.